Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Short summary

In low-risk HPV-positive oropharyngeal cancer, adding cetuximab to radiotherapy resulted in significantly worse 2-year overall survival (89.4% vs 97.5% with cisplatin) and higher recurrence rates (16.1% vs 6.0% with cisplatin), with no reduction in toxicity.

AI-generated from the title and abstract; the full text is not read.